Abstract | BACKGROUND: CASE PRESENTATION: We used sirolimus to treat three infants with diffuse CHI. Diagnosis was confirmed clinically, biochemically and by genetic testing. Homozygous mutations in KCNJ11, ABCC8 and KCNJ11 were identified in infants 1, 2 and 3, respectively. Each infant had received the therapy for at least 2 months with close monitoring of glycemic response, serum insulin and C-peptide. None of the infants responded to the therapy. CONCLUSIONS: We conclude that sirolimus is less effective in the treatment of diffuse CHI in patients with severe mutations in the homozygous state compared with those with the mutations in the heterozygous.
|
Authors | Rana Al-Balwi, Mohsen Al-Atawi, Ahlam Al-Otaibi, Omar Babiker, Angham Al-Mutair |
Journal | Journal of pediatric endocrinology & metabolism : JPEM
(J Pediatr Endocrinol Metab)
Vol. 30
Issue 9
Pg. 1013-1017
(Aug 28 2017)
ISSN: 2191-0251 [Electronic] Germany |
PMID | 28787272
(Publication Type: Case Reports)
|
Chemical References |
- ABCC8 protein, human
- Blood Glucose
- Kir6.2 channel
- Potassium Channels, Inwardly Rectifying
- Sulfonylurea Receptors
- Sirolimus
|
Topics |
- Blood Glucose
- Congenital Hyperinsulinism
(blood, drug therapy, genetics)
- Female
- Humans
- Infant
- Male
- Mutation
- Potassium Channels, Inwardly Rectifying
(genetics)
- Sirolimus
(therapeutic use)
- Sulfonylurea Receptors
(genetics)
- Treatment Outcome
|